Sunitinib inhibits inflammatory corneal lymphangiogenesis

Area of Science:

• Ophthalmology
• Vascular Biology
• Pharmacology

Background:

• Corneal neovascularization (NV) is a significant cause of vision impairment.
• Targeting both blood and lymphatic vessels is crucial for treating NV.
• Multi-target tyrosine kinase inhibitors offer a potential therapeutic strategy.

Purpose of the Study:

• To investigate the antilymphangiogenic and antiangiogenic effects of sunitinib in a mouse model of corneal NV.
• To elucidate the underlying mechanisms of sunitinib's action on corneal NV.

Main Methods:

• Corneal NV was induced via thermal cauterization in mice.
• Sunitinib malate was administered orally.
• Immunohistochemistry was used to quantify vascular and inflammatory cells.
• RT-PCR analyzed the expression of key angiogenic and lymphangiogenic factors.
• In vitro assays (aortic and lymphatic ring assays) assessed sunitinib's direct effects.

Main Results:

• Sunitinib significantly reduced corneal lymphangiogenesis and angiogenesis.
• Treatment decreased F4/80+ cell infiltration and expression of VEGF-A and VEGF-C.
• In vitro, sunitinib inhibited angiogenesis but not lymphangiogenesis directly.
• Sunitinib counteracted macrophage-conditioned medium-induced angiogenesis and lymphangiogenesis.
• The drug blocked VEGFR-2 phosphorylation induced by macrophage-derived VEGF-A.

Conclusions:

• Sunitinib demonstrates potent antihemangiogenic and antilymphangiogenic properties in vivo.
• Its efficacy is mediated by reducing inflammatory cell recruitment and their secreted factors.
• Sunitinib represents a promising therapeutic agent for managing corneal neovascularization.